Moreover, it was shown that β-elemene with cetuximab resulted in downregulation of the mesenchymal markers (Vimentin, N-cadherin, Slug, Snail, and MMP-9) and upregulation of epithelial marker E-cadherin in HCT116 and Lovo cells, indicating the combo treatment may suppress cell migration of KRAS mutant CRC cells by inhibiting EMT.23 Here, KRAS is linked to colorectal carcinoma.